Exelixis

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

Retrieved on: 
星期二, 五月 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Exelixis, Calendar, Conference

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m.
  • ET / 3:20 p.m. CT / 1:20 p.m. PT in Chicago.
  • To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading.
  • A replay will also be available at the same location for at least 30 days.

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Retrieved on: 
星期二, 五月 7, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Bank of America, BofA Securities, Calendar, Exelixis, RBC Capital Markets, Conference

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:
    BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20 p.m.
  • Citizens JMP Life Sciences Conference: Exelixis is scheduled to present at 9:30 a.m.
  • RBC Capital Markets 2024 Global Healthcare Conference: Exelixis is scheduled to present at 2:35 p.m.
  • To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading.

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

Retrieved on: 
星期二, 二月 27, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Exelixis, Calendar, Conference

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March:

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March:
    TD Cowen 44th Annual Health Care Conference: Exelixis is scheduled to present at 10:30 a.m.
  • Leerink Partners Global Biopharma Conference 2024: Exelixis is scheduled to present at 9:20 a.m.
  • Barclays 26th Annual Global Healthcare Conference: Exelixis is scheduled to present at 10:45 a.m.
  • To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading.

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Retrieved on: 
星期三, 二月 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cancer, PFS, PD, KIT, Toxicity, Anemia, Roche, Research and development, Security (finance), Part, Hypoxia, PD-1, Belzutifan, Safety, Income tax, Death, Access code, Administration, Exelixis, Webcast, Patient, Acceleration, TIGIT, Plasma, G&A, Pancreatic cancer, AXL, CD73, Pharmaceutical industry

Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.

Key Points: 
  • Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.
  • The companies also plan to initiate a Phase 2 trial to evaluate domvanalimab plus zimberelimab in a new disease setting.
  • Arcus will host a conference call and webcast today, February 21, at 2:00 PM PT / 5:00 PM ET to discuss its fourth-quarter and full-year 2023 financial results and pipeline updates.
  • To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com .

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

Retrieved on: 
星期四, 二月 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Exelixis, Calendar, Conference

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February:

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February:
    Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference: Exelixis is scheduled to present at 9:00 a.m.
  • ET / 6:00 a.m. PT on Thursday, February 8 in New York City.
  • Oppenheimer 34th Annual Healthcare Life Sciences Conference: Exelixis is scheduled to present virtually at 12:40 p.m.
  • To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading.

Acadia Announces Additions to Executive Team

Retrieved on: 
星期三, 一月 31, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Rett syndrome, Pfizer, Capital punishment, Senior, Bristol Myers Squibb, Tulane University, General counsel, Delusion, Law, Boehringer Ingelheim, Schizophrenia, DevOps, Drug development, Patient, FDA, Prader–Willi syndrome, Weil, Gotshal & Manges, Corporation, Regulatory affairs, ACAD, University of Florida, Medivation, Exelixis, University, Hallucination, Economics, Myenteric plexus, Management

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team.
  • Following a transition period, Austin D. Kim, Executive Vice President, General Counsel and Secretary will be leaving Acadia to pursue other opportunities.
  • “I’m thrilled to announce these two important additions to the team,” said Steve Davis, Chief Executive Officer.
  • “Jennifer brings strong executive leadership skills with over 20 years of legal, strategy and business experience at emerging, rapidly growing and Fortune 500 life sciences companies.

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Retrieved on: 
星期四, 一月 25, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Exelixis, Huntsman Cancer Institute, Patient, Prostate cancer, PST, Progression-free survival, NHT, OS, ASCO, Survival, Clinical research, University, Society, Metastasis, RECIST, PFS, BIRC, ITT

The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).

Key Points: 
  • The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).
  • The PFS analysis was conducted in the first 400 randomized patients in the intent-to-treat (PFS ITT) population and per protocol.
  • While a trend toward OS improvement was observed, the data were immature and did not meet the threshold for statistical significance.
  • The PFS benefit and the trend for an OS benefit were observed across subgroups of high-risk populations, as presented in Table 1.

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Retrieved on: 
星期一, 一月 22, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Exelixis, Checkmate, Patient, Progression-free survival, OS, Partnership, RCC, ASCO, Survival, Society, Risk, Metastasis, PFS, Abstract, Safety, Liver, Confidence interval, GU, BMY, Sunitinib, IMDC, Pharmaceutical industry

Superior overall survival (OS) was also observed in patients treated with the combination.

Key Points: 
  • Superior overall survival (OS) was also observed in patients treated with the combination.
  • ORR (secondary endpoint): The combination regimen showed durable response improvements, doubling the ORR compared to sunitinib (55.7% vs. 27.7%, respectively).
  • ORR: In patients with intermediate-/ poor-risk, ORR was more than doubled at 52.6% with Opdivo and CABOMETYX vs. 23.0% with sunitinib.
  • In those with favorable risk profiles, the number of patients who achieved CR was doubled (16.2% vs. 8.3%) with the combination regimen.

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

Retrieved on: 
星期四, 一月 18, 2024
Pharmaceutical, Health, Oncology, European Patent Convention, Exelixis, EPO, European Medicines Agency, Tablet, Hearing, Patent, Stada Arzneimittel

Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposition Division of the European Patent Office (EPO).

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposition Division of the European Patent Office (EPO).
  • The three-member panel of the Opposition Division rejected all grounds of opposition, thus upholding the patent as granted.
  • The patent at issue, which expires on July 18, 2031, covers tablet formulations of cabozantinib, including the tablet formulation approved as CABOMETYX® (cabozantinib) tablets by the European Medicines Agency.
  • The decision is specific to the European patent at issue and is subject to appeal to the EPO Technical Boards of Appeal.

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Retrieved on: 
星期四, 一月 4, 2024
Biology, Sensei, Lung cancer, CD28, CRC, Neoplasm, Tumor microenvironment, Biotechnology, IND, DLT, FDA, VSIG4, CMO, Research, Colorectal cancer, MSS, Physician, Cancer, Pharmacokinetics, CD39, Head, Novartis, Exelixis, Part-time, Histology, VISTA, American College, Genentech, Internal medicine, Oncology, Patient, Safety, Therapy, NSCLC, Pharmaceutical industry

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.

Key Points: 
  • BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.
  • In the monotherapy dose escalation arm, patients have cleared all planned dosing cohorts of 0.3, 1, 3, 10 and 15 mg/kg.
  • Anticipated milestones for the SNS-101 Phase 1/2 clinical trial include:
    Sensei announces that Ron Weitzman, M.D., F.A.C.P., has joined Sensei as part-time Chief Medical Officer.
  • As a result, Sensei will pause IND-enabling work on its preclinical-stage TMAb programs, including SNS-102 (VSIG4), SNS-103 (CD39) and SNS-201 (VISTAxCD28).